UAE Pharmaceutical Sector Accelerates Local Manufacturing and Drug Security

Rapid Growth in the Pharmaceutical Sector

The UAE is emerging as a leader in the pharmaceutical industry, marked by a significant shift towards local manufacturing and drug security. This transformation is driven by a comprehensive regulatory and investment vision that supports national companies in their transition from planning to actual execution. Dr. Basem Al-Braihme, CEO of Global Pharma, highlighted an unprecedented acceleration in the registration and launch of new drugs, with the company successfully registering and launching 25 products in 2025 alone.

This growth reflects the effectiveness of the regulatory environment and government backing for the sector. Al-Braihme emphasized that the current phase is characterized by rapid responses from both regulatory bodies and the private sector, resulting in remarkable operational outcomes, including the production of 44.9 million pharmaceutical units in 2025 without any recalls or workplace injuries.

Commitment to Quality and Sustainability

Global Pharma’s growth is underpinned by an integrated system that leverages advanced manufacturing capabilities and a highly experienced workforce. Despite ending its partnership with a global company in 2019, the firm has maintained international standards, which has bolstered the quality of its products and its market position. Al-Braihme stated that quality is a fundamental commitment that cannot be compromised, noting that the company has not recorded any product recalls for over 27 years, a testament to the trust it has earned from doctors, pharmacists, and patients.

The importance of local pharmaceutical manufacturing has become increasingly evident, especially in light of global challenges that necessitate self-sufficiency and robust supply chains. Al-Braihme remarked that local manufacturing is essential for achieving drug security, citing the UAE’s experience during the COVID-19 pandemic, which showcased the capacity of national companies to respond swiftly, whether in producing sanitizers or specialized medications.

Strategic Expansion and Community Responsibility

Global Pharma has expanded its reach to over 12 countries, demonstrating its competitiveness in both regional and international markets, driven by manufacturing quality and operational efficiency. The UAE’s integrated environment, characterized by flexible regulations and investment capabilities, positions the country as a leading regional hub for the pharmaceutical industry. Al-Braihme noted that the UAE’s supportive legal framework and qualified human resources enhance the competitiveness of national companies.

Looking ahead, Global Pharma is focused on expanding its presence in key markets, particularly Saudi Arabia, while also eyeing growth opportunities in Africa—one of the fastest-growing markets despite regulatory and supply chain challenges. The company’s connection with Dubai Investments is pivotal, facilitating access to new markets, including Angola, which is developing manufacturing facilities to support expansion in Africa.

Innovations in Sustainability and Community Engagement

Global Pharma is increasingly prioritizing sustainability in its operations and products. The company was among the first in the UAE to adopt Braille-labeled medicine packaging for the visually impaired and QR technologies to enhance patient information accessibility. Additionally, it is implementing initiatives in renewable energy, water recycling, and reducing paper usage through digital transformation, achieving a 90% digitization rate in its quality laboratories, which translates to a reduction of approximately nine tons of paper annually.

In terms of corporate social responsibility, Global Pharma has supported various humanitarian initiatives, including direct aid to Lebanon and contributions to relief efforts in Gaza through government-approved programs.

Future Growth and Strategic Vision

Global Pharma is actively pursuing expansion plans, having already increased its facility space in the Dubai Investment Park by 20 to 30%. The company is also integrating advanced manufacturing technologies that include modern pharmaceutical systems, enhancing product diversity and production capacity. As it moves into a new growth phase, Global Pharma is driven by a clear strategic vision, supported by the UAE’s conducive environment and its ongoing commitment to strengthening its regional and global presence.

Frequently Asked Questions

What is the current state of the UAE pharmaceutical sector?

The UAE pharmaceutical sector is rapidly growing, focusing on local manufacturing and drug security, with significant government support.

How has Global Pharma contributed to this growth?

Global Pharma has launched 25 new products in 2025 and produced 44.9 million pharmaceutical units without recalls.

What role does sustainability play in Global Pharma’s operations?

Global Pharma prioritizes sustainability through initiatives like Braille packaging, renewable energy, and digital transformation.

Which markets is Global Pharma targeting for expansion?

Global Pharma is expanding into key markets such as Saudi Arabia and Africa, while also considering European and American markets.

How does the UAE support its pharmaceutical companies?

The UAE provides a supportive regulatory environment, investment opportunities, and qualified human resources to enhance competitiveness.